Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Chemotherapy-Induced Neutropenia Treatment Market By 2029?
The chemotherapy-induced neutropenia treatment market has experienced robust growth over the past few years. Projections indicate it will expand from $0.59 billion in 2024 to reach $0.62 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.4%. Historically, this expansion has been driven by increasing cancer incidence rates, rising chemotherapy adoption, a growing geriatric population, high hospitalization rates due to infections, and expanding oncology drug pipelines.
The chemotherapy-induced neutropenia treatment market is projected to experience robust expansion in the coming years. It is expected to reach $0.76 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.2%. This growth during the forecast period can be attributed to an escalating demand for targeted neutropenia therapies, increased investment in oncology research and development, a heightened focus on outpatient care, the expanding utilization of biosimilars, and a rising awareness of infection prevention. Prominent trends within the forecast period include the development of long-acting granulocyte colony-stimulating factor therapy (G-CSF) agents, a greater adoption of combination therapies, an increasing preference for home-based care solutions, a surge in biosimilar approvals, and the integration of digital health monitoring tools.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
Which Drivers Are Shaping The Chemotherapy-Induced Neutropenia Treatment Industry’s Market Share?
The rising occurrence of cancer is projected to drive forward the expansion of the chemotherapy-induced neutropenia treatment market. Cancer constitutes a collection of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. This increase in cancer diagnoses stems from an aging demographic, given that elderly individuals face an elevated likelihood of developing cancer owing to accumulated genetic alterations and a gradual weakening of immune capabilities. Chemotherapy-induced neutropenia treatment plays a supportive role in cancer care, mitigating infection risks via immune system bolstering and enabling patients to undergo chemotherapy with fewer pauses. Furthermore, it improves treatment results by lessening complications, thus enhancing overall patient safety and their quality of life. As an illustration, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government entity, indicated that the count of cancer cases identified in Australia climbed to 160,570 in 2022, representing an increment of 3,789 cases from the 156,781 recorded in 2021. Consequently, the expanding incidence of cancer serves as a primary driver for the growth of the chemotherapy-induced neutropenia treatment market.
How Is The Chemotherapy-Induced Neutropenia Treatment Market Segmented?
The chemotherapy-induced neutropenia treatmentmarket covered in this report is segmented –
1) By Type: Antibiotic Therapy; Granulocyte Colony-Stimulating Factor Therapy (G-CSF); Granulocyte Transfusion; Other Types
2) By Route of Administration: Subcutaneous; Intravenous
3) By Indication: Solid Tumors; Hematological Malignancies; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics; Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim; Pegfilgrastim; Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion; Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy; Stem Cell Therapy; Immunomodulatory Therapy
What Are The Latest Industry Trends Transforming The Chemotherapy-Induced Neutropenia Treatment Market?
Major companies within the chemotherapy-induced neutropenia treatment market are concentrating on developing innovative products and securing approvals, such as long-acting formulations, to enhance patient convenience, lower dosing frequency, and boost treatment adherence. Long-acting formulations are defined as drug preparations designed to gradually release active ingredients over an extended period, thereby reducing the frequency of administration. For instance, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for Udenyca Onbody, an innovative, ready-to-use on-body injector. This device, containing a long-acting formulation, automatically delivers pegfilgrastim approximately 27 hours after chemotherapy, removing the requirement for a next-day injection. Udenyca Onbody improves the patient experience by guaranteeing timely prophylactic treatment of chemotherapy-induced neutropenia while simultaneously lessening clinic visits and enhancing adherence.
Which Leading Companies Dominate The Chemotherapy-Induced Neutropenia Treatment Market Share?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
Download The Full Report For Exclusive Market Findings:
Which Region Currently Holds The Largest Share Of The Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Chemotherapy-Induced Neutropenia Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Neutropenia Treatment Market 2025, By The Business Research Company
Ambulatory Iv Infusion Pumps Global Market 2025
https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market
Chemotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model